Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels

What Was Tested

Researchers studied Angiotensin II and Bradykinin in this clinical trial publication.

The researchers investigated the effects of sunitinib on blood pressure (BP), its circadian rhythm, and potential mechanisms involved, including the endothelin-1 system, in 15 patients with metastatic renal cell carcinoma or gastrointestinal stromal tumors.

In addition, the researchers investigated in rats the effect of sunitinib on BP, serum endothelin-1 levels, coronary microvascular function, cardiac structure, and cardiac mitochondrial function.

Who Took Part

The study group was 15 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The methods mention a period of 4 weeks.

What Was Measured

The researchers investigated the effects of sunitinib on blood pressure (BP), its circadian rhythm, and potential mechanisms involved, including the endothelin-1 system, in 15 patients with metastatic renal cell carcinoma or gastrointestinal stromal tumors.

In addition, the researchers investigated in rats the effect of sunitinib on BP, serum endothelin-1 levels, coronary microvascular function, cardiac structure, and cardiac mitochondrial function.

Topics PubMed links to this paper include Angiotensin II, Blood Pressure, Bradykinin, Carcinoma, Renal Cell, Cells, Cultured, Coronary Circulation and Endothelial Cells.

What This Means in Plain Language

This is a clinical trial of Angiotensin II and Bradykinin in 15 patients over 4 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2010 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Angiotensin II compound page and the Bradykinin compound page, all human trials.